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Abstract
Recently, structural variation in the genome has been implicated in many complex diseases. Using genomewide single
nucleotide polymorphism (SNP) arrays, researchers are able to investigate the impact not only of SNP variation, but also of
copy-number variants (CNVs) on the phenotype. The most common analytic approach involves estimating, at the level of
the individual genome, the underlying number of copies present at each location. Once this is completed, tests are
performed to determine the association between copy number state and phenotype. An alternative approach is to carry out
association testing first, between phenotype and raw intensities from the SNP array at the level of the individual marker, and
then aggregate neighboring test results to identify CNVs associated with the phenotype. Here, we explore the strengths
and weaknesses of these two approaches using both simulations and real data from a pharmacogenomic study of the
chemotherapeutic agent gemcitabine. Our results indicate that pooled marker-level testing is capable of offering a dramatic
increase in power (w12-fold) over CNV-level testing, particularly for small CNVs. However, CNV-level testing is superior
when CNVs are large and rare; understanding these tradeoffs is an important consideration in conducting association
studies of structural variation.
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Introduction
The analysis of individual human genomes has revealed an
unexpected amount of variability in the form of duplication and
deletion of genomic regions [1,2]. Since then, a number of studies
have shown that copy-number variation plays a large role in
genetic diversity [3,4]. Other studies have identified associations
between copy-number variation and various diseases, including
Crohn’s disease, psoriasis, schizophrenia, and autism [5–9].
Because humans have two copies of each chromosome, most
individuals have two copies of a given genomic segment. Copy-
number variation exists when an individual has one or more
deletions or duplications of that segment, resulting in a different
number of copies. Such an individual is said to possess a CNV at
that region, while the normal, or copy-neutral, individuals do not.
This article discusses statistical approaches for conducting
genetic association studies of copy-number variation. Such studies
attempt to identify associations between a phenotype, such as
disease state or drug response phenotype, and genetic variation in
the form of changes in copy number. There are several techniques
for measuring copy-number variation, including array compara-
tive genomic hybridization and next-generation sequencing. We
focus here on the detection of copy-number changes using data
from genomewide single nucleotide polymorphism (SNP) arrays,
although many of the issues that we explore are relevant regardless
of the platform used to obtain the copy-number measurements.
The main advantage of SNP arrays is that vast amounts of this
type of data have already been collected in pursuit of identifying
associations involving SNPs. The convenience and low cost of re-
analyzing these data for copy-number variation has prompted a
number of studies, and should continue to do so for years to come.
We compare two strategies for CNV association testing. Each
strategy consists of two stages. In the first approach, which we refer
to as CNV-level testing, stage I consists of estimating the number of
copies present at all segments of the genome, for each individual.
This is often referred to as ‘‘CNV calling.’’ Next, stage II consists
of carrying out a genetic association test at every segment for
which copy-number variability exists. A number of articles [10–
13] have compared various methods for CNV calling. Our
approach here is different; we are interested in comparing this
family of approaches with an entirely different approach which
does not involve CNV calling.
In this second approach, which we refer to as marker-level testing,
stage I consists of carrying out an association test at every genetic
marker using raw intensity data from the SNP array. Since CNVs
span multiple markers, the presence of a single CNV that affects
the phenotype will elevate the test statistics for several nearby
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pooling test results across neighboring markers to determine CNV
regions associated with the phenotype.
Because the above approaches consist of two stages, each
approach risks losing information in the first stage that may
diminish power in the second stage. We illustrate that this is indeed
a concern, and furthermore, that the type of information lost by
each approach is quite different. This has strong implications for
the power of each method to detect various forms of CNV-
phenotype associations. After a more detailed description of the
data from such studies, we illustrate the two approaches and then
compare them using both real and simulated data.
Methods
Data
The data in this article comes from a pharmacogenomic study
of gemcitabine, a commonly used treatment for pancreatic cancer.
In this section, we describe the design of the study, the general
characteristics of data arising from such studies, and how this data
was used to create spike-in simulated data sets which allow us to
estimate and contrast the power of the CNV- and marker-level
testing approaches.
Gemcitabine pharmacogenomic study
The gemcitabine pharmacogenomic study [14,15] was carried
out on the Human Variation Panel (HVP), a cell based model
system. The HVP consists of EBV-transformed B lymphoblastoid
cells derived from Caucasian-American (CA), African-American
(AA) and Han Chinese-American (HCA) subjects (Coriell Institute,
Camden, NJ). Gemcitabine drug cytotoxicity data were collected
at eight drug dosages (1000, 100, 10, 1, 0.1, 0.01, 0.001, and
0.0001 uM) [14]. Estimation of the drug response phenotype IC50
(the effective dose that kills 50% of the cells) is then completed
using a four parameter logistic model [16]. Genotyping of markers
for the cell lines was completed using the Illumina HumanHap
550K and HumanHap510S at the Genotyping Shared Resources
at the Mayo Clinic in Rochester, MN, which consists of a total of
1,055,048 markers [15,17]. In addition to the called genotypes for
the SNP markers, we have the raw intensity data to be used in
CNV analysis. One hundred seventy-four cell lines (60 Caucasian,
54 African American, 60 Han Chinese American) had both
gemcitabine cytotoxicity measurements and genome-wide marker
intensity data. To compare the two approaches for CNV analysis
for a pharmacogenomic study, we chose one chromosome
(chromosome 3) from the genome-wide data. Raw data was
normalized according to the procedure outlined in Barnes et al.
(2008) [18], which corrects for a number of potential biases,
including batch effects and differences in hybridization intensity
among the probes. To control for the possibility of population
stratification, which can lead to spurious associations, we used the
method developed by Price et al. (2006) [19], which uses a
principal components analysis to adjust for stratification.
General structure of CNV data from SNP arraysThe raw data
that arises from the gemcitabine study, or any similar study
involving genome-wide SNP arrays such as those manufactured by
Illumina or Affymetrix, consists of two intensity measurements for
each SNP, corresponding to the A and B alleles [20,21]. These
intensities are then transformed into polar coordinates, with R
representing the overall intensity and h representing the relative
contribution from each allele. To account for systematic
differences in intensity between the two alleles, one considers the
ratio between R and the expected value of R given neutral copy
number. Finally, a log transformation is applied. The result (the
log R ratio, or LRR) serves as a continuous measurement of copy
number and is vaguely normal in distribution, though with thicker
tails. In addition to SNP markers, many genotyping arrays now
include non-polymorphic markers specifically for the purpose of
copy-number measurement. We use the generic term marker to
refer to any position on the genome in which an intensity
measurement is obtained.
An illustration of the what this type of data looks like in the
presence of a putative CNV is presented in Figure 1. As the figure
illustrates, there is a substantial amount of noise present in the data
relative to the magnitude of the shift in LRR. Because of this noise,
the drop in LRR may not be obvious at a glance. However, the
statistical evidence is fairly convincing: a t-test of whether the
mean LRR for the markers in the gray region is equal to that of
the surrounding markers has p~3|10{8. Clearly, there is a need
for good statistical methods to distinguish signals from noise.
Spike-in simulations
In order to study the power of CNV- and marker-level testing
approaches, we must be able to simulate CNVs and their
corresponding LRR intensity measurements. The accuracy of
these power estimates is affected by how realistic the simulated
data is, so we give careful thought here to simulating this data in as
realistic a manner as possible. The basic design of our simulations
is use real data from the gemcitabine study and ‘‘spike’’ in a signal,
then observe the frequency with which we can recover that signal.
We used circular binary segmentation (described in ‘‘CNV-level
testing’’) to estimate each sample’s underlying mean LRR at every
position along the chromosome, then subtracted the estimated
mean from the actual LRR measurement to obtain a matrix of
residuals representing the noise accompanying the measurement
of LRR. We restricted this effort to chromosome 3 of the
gemcitabine pharmacogenomic study, resulting in a residual
matrix containing 172 samples and 70,542 markers.
We then used these residuals to simulate LRR noise over short
genomic regions in which a single simulated duplication is present.
Letting i denote subjects and j denote markers, the following
variables are generated: zi, an indicator for the presence or
absence of a CNV in individual i; xij, the LRR measurement at
marker j for individual i; and yi, the phenotype. For each
simulated data set, 200 markers were randomly selected from
chromosome 3. The LRR measurement error for simulated
subject i was then taken from the observed measurement errors at
those markers for a randomly chosen cell line in the data from the
gemcitabine study. The random selection of markers from
throughout the chromosome removes the possibility of bias arising
from correlation among the intensities of nearby markers, which
otherwise may arise from missed CNVs during the CBS estimation
or genomic ‘‘waves’’ caused by local variation in genomic GC
content [22,23].
Thus, within a simulated data set, all subjects are studied with
respect to the same genetic markers, but the markers vary from
data set to data set. Simulating the data in this way preserves all
the features of outliers, heavy-tailed distributions, skewness,
unequal variability among markers, and unequal variability
among subjects that are present in real data. A 200 marker
region corresponds to, on average, a 560 kb region of chromo-
some 3. We varied the length of the CNV from 10 to 50 markers,
corresponding to a size range of 26 to 137 kb. For the Illumina
Human1M-Duo BeadChip, which has a median spacing of 1.5 kb
between markers, these numbers of markers would correspond to
simulating a 300 kb region with CNV size ranging from 15 to
75 kb.
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cohort study in which the outcome is continuous and a case-
control study in which the outcome is binary. In the cohort study,
the CNV indicator, zi, is generated from a Bernoulli distribution,
where Pr(zi~1) is the frequency of the CNV in the population;
subsequently, yiDzi is generated from a normal distribution whose
mean depends on zi. In the case-control study, the outcomes are
fixed (in our simulation, half of the subjects were cases and the
other half controls), whereas ziDyi is generated from a Bernoulli
distribution with a probability given by Bayes’ rule that depends
on the frequency of the CNV in the population (c), the prevalence
of the disease in the normal population (d0), and the penetrance of
the genetic mutation (d1):
Pr(zi~1Dyi~1)~
cd1
cd1z(1{c)d0
Pr(zi~1Dyi~0)~
c(1{d1)
c(1{d1)z(1{c)(1{d0)
Note that in both sampling designs, the phenotype and LRR are
conditionally independent given the latent copy-number status zi.
As mentioned earlier, the LRR values, fxijg, derive from the
observed residuals in the real data. To this noise, we add a signal
that depends on the presence of the simulated CNV, zi. The added
signal is equal to zero unless the simulated genome contains a
CNV encompassing the jth marker; otherwise the added signal is
equal to the standard deviation of the measurement error times the
signal to noise ratio. Our simulations employed a signal-to-noise
ratio of 0.8, which corresponded roughly to a medium-sized
detectable signal based on our inspection of the gemcitabine data.
An illustration of the spike-in process is given in Figure 2.
For the simulations presented in the remainder of the article, we
used a sample size of n~1,000. For continuous outcomes, we used
an effect size (change in mean divided by standard deviation) of
0.4. For the case control studies, we assumed a rare disease
(d0~0:01) and a CNV which confers a relative risk of 2. All
association tests were conducted with a nominal overall type I
error rate of 0.05.
CNV-level testing
The idea behind CNV-level testing is to first separate each
individual’s genome into regions of constant copy number and
then to use those results for subsequent association testing. Thus,
the first challenge is to develop a method for detecting departures
from copy-neutral status.
Several methods have been proposed for this task; among the
most prominent are hidden Markov models [24,25], circular
binary segmentation [26,27], and the fused lasso [28,29]. We focus
here on circular binary segmentation, which has been found to
compare favorably with other methods [10,11]. However, as we
will comment on in the discussion, our main conclusions regarding
the fundamental differences between CNV-level and marker-level
tests would likely apply to the other methods as well.
The main idea behind circular binary segmentation (CBS) is as
follows. For each chromosome,
1. Form the sequence of LRR intensities into a circle by joining
the first and last markers
2. For all possible ways of dividing up the circle into complimen-
tary arcs, compute the t-test statistic for a difference in means
between the two arcs
3. If the maximum of these test statistics exceeds its null
distribution critical value, segment the circle there
4. Repeat recursively for the segmented arcs until no more
significant segments can be found
To carry out this analysis, we used the R package DNAcopy
(available at http://www.bioconductor.org/packages/release/
bioc/html/DNAcopy.html), which obtains the critical values in
step 3 above using a permutation testing approach. For details of
this procedure and its implementation, see [26,27]. The output of
this procedure is an estimation, at every position along the
genome, of the mean LRR at that position. These estimates, which
we denote ^ m mk, are piecewise constant over arc k, and therefore also
provide an estimation of the CNV structure of each individual’s
genome.
Once these estimates have been obtained, the second stage in
CNV-level testing is to carry out the association test. In practice,
this can be fairly complicated, for at least three reasons: (1) the test
can be based on either a continuous measure, ^ m mk or a
discretization such as whether ^ m mk represents a duplication (gain),
deletion (loss), or normal value. (2) Overlapping CNVs do not
Figure 1. Example of LRR data for a putative CNV on Chromosome 3 for a cell line in the gemcitabine study. The gray region denotes
the estimated boundary of the CNV. The points in the gray region have a mean LRR of 20.98; the surrounding points have a mean of 20.11.
doi:10.1371/journal.pone.0034262.g001
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partially overlapping CNVs represent the same CNV or different
CNVs can be a rather complicated decision, especially when the
sample size is reasonably large, as the number of overlap patterns
can be considerable. (3) Because CNVs from different individuals
do not overlap perfectly, the CNV-level tests are correlated; this
complicates efforts to correct for multiple testing. For our
simulations, we avoid these complications by focusing only on a
small genomic region with a single CNV and basing the test on
whether a CNV is detected or not, thereby skirting the above
complications. We then conduct either a t-test or Fisher’s exact
test, depending on whether the phenotype is continuous or binary.
However, it is worth noting that applications of CNV-level tests to
actual, genomewide data must contend with the above three
issues; this is discussed further in the Results section.
An important consideration in the use of CBS for subsequent
association testing is the threshold used to declare a CNV present.
If the threshold is too high, true CNVs will go undetected; if this
threshold is too low, false positives will occur as neutral regions are
called as CNVs. The tradeoff between false positives and false
negatives depends on the frequency of the CNV, as Table 1
demonstrates.
As the table shows, false positives are a larger problem when the
CNV is rare than when it is common. While highly stringent false
positive rates of 0.001 and 0.01 perform well when the CNV is
rare (5% frequency in the population), the more liberal critical
value of 0.1 attains the best power when the CNV is common
(20% population frequency). This is not surprising. One would
anticipate that power is roughly proportional to misclassification
rate; misclassification rate in turn is dominated by false positives
when CNVs are rare. For more common CNVs, however, highly
stringent thresholds cause problems as false negatives become
frequent.
In any real study, of course, there will presumably be a mixture
of common and rare CNVs that may be associated with the
phenotype. The above results indicate that a threshold of 0.01 is
fairly robust over a realistic range of CNV frequencies. This trend
was observed across a range of different marker sizes (data not
shown); accordingly, we use this value for subsequent simulations
involving CNV-level tests.
Marker-level testing
A lesser known alternative to CNV-level testing is marker-level
testing, in which association testing between copy number and
phenotype is carried out at the level of the single marker. These
tests make no effort to call CNVs as present or absent; instead,
they utilize intensity as a continuous measurement of copy number
at each marker. For example, if our phenotype is continuous, each
marker-level test may derive from a linear regression model. Such
a model may involve adjustments for additional factors, such as
race and age. Figure 3 illustrates the basic idea: three marker-level
tests are depicted, as well as a plot of the resulting {log10 (p)
values along the chromosome. As the figure illustrates, each
individual test is not particularly convincing due to the high
variability of the LRR measurements, but the aggregation of a
large number of tests with low p-values in close genetic proximity
to each other strongly suggests a copy number-phenotype
association.
The second stage in marker-level testing is to identify these
regions in which low p-values have aggregated. This requires a
systematic method for pooling information across neighboring
hypothesis tests. We propose here to pool test results by using
circular binary segmentation (described in ‘‘CNV-level testing’’) on
the p-values. Certainly, there are other possibilities (see Discus-
sion). Our purpose in this paper, however, is to broadly illustrate
the strengths and weaknesses of marker-level testing versus CNV-
level testing, and to that end we restrict attention here to CBS as
the method by which the genome is segmented in both testing
approaches.
One factor we do explore, however, is the effect of transforming
the p-values. In particular, one may imagine performing CBS on
the p-values themselves, on {log10 (p),o ro nW{1(p), where W is
the CDF of the standard normal distribution. The last transfor-
mation (the so-called ‘‘probit’’ transformation) is motivated by the
idea that the resulting quantity will follow a normal distribution
under the null, which should provide maximum power in the
Figure 2. Example of LRR data for a simulated CNV. Left: The noise, randomly drawn from among the observed measurement errors for a
single subject. Middle: The spiked-in signal. Right: The resulting simulated data, which looks qualitatively similar to the real CNV in Figure 1.
doi:10.1371/journal.pone.0034262.g002
Table 1. Effect of CNV-calling threshold (a) on the power to
detect a CNV.
Calling
threshold
0.001 0.01 0.1
CNV 5% 17.9 29.0 22.1
Frequency 10% 32.5 55.4 52.8
20% 50.0 82.0 88.8
Continuous outcome, 10,000 replications per cell, CNV size=30 markers).
doi:10.1371/journal.pone.0034262.t001
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results from using this transformation is illustrated in Table 2,
based on simulation results. We therefore use the probit
transformation for marker-level testing when comparing associa-
tion testing approaches in the Results section. It is worth noting
that the {log10 (p) transformation is highly sensitive to low p-
values. Although this is seemingly attractive, it decreased the
power. This raises the question of whether some other method of
marker-level test aggregation might be able to harness this feature
more effectively than CBS. This is an interesting question for
future research, but beyond the scope of this paper to address.
Results
Simulated data
Using the simulation setup described in ‘‘Spike-in simulations’’,
we compared the power of both CNV- and marker-level
approaches while varying study design, CNV prevalence, and
CNV size. For each setting, 10,000 independent data sets were
generated and analyzed. Power was defined as the fraction of time
a CNV-phenotype association was declared. Note that this does
not take into account fraction of overlap. Certainly, one would
prefer a method that not only detects CNV associations but
correctly identifies their boundaries; we focus only on yes/no
detection of copy-number association here.
In the absence of spiked-in signal, each approach preserved the
type I error rate of 5% for both study designs. The power of each
approach to detect genetic associations in the presence of a spiked-
in, causative CNV is illustrated in Figure 4. The figure illustrates a
very interesting contrast between the two approaches. Relative to
marker-level testing, CNV-level testing works better for large, rare
CNVs. On the other hand, marker-level testing performs better
Figure 3. Illustration of marker-level testing. Top: Marker-level tests at three markers for the gemcitabine study. The phenotype (IC50, a
continuous outcome described in ‘‘Gemcitabine pharmacogenomic study’’) is plotted as a function of LRR, along with the regression line. The p-
values for the three F-tests are, respectively, from left to right. 0.25, 0.0008, and 0.0008, respectively, from left to right. Bottom: Plot of {log10 (p)
from the marker-level tests as a function of position along the chromosome. The three tests from the top part of the figure are plotted in red.
doi:10.1371/journal.pone.0034262.g003
Table 2. Effect of various transformations of p-value prior to
application of CBS on the power to detect a CNV.
No Transformation
pooling None Probit {log10
CNV 5% 6.8 8.6 8.6 6.7
frequency 10% 15.2 30.8 34.2 24.1
20% 54.0 82.9 88.0 76.8
Continuous outcome, 10,000 replications per cell, CNV size=30 markers.
‘‘Power’’ here refers to the probability that a segment in which low p-values
have aggregated can be separated from the test results from surrounding
markers. The ‘‘no pooling’’ analysis (which implements a Bonferroni correction
to maintain the correct overall type I error rate) is included to illustrate the
power gained by pooling information across nearby markers.
doi:10.1371/journal.pone.0034262.t002
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associations involving large, common CNVs with adequate power,
while neither method was able to detect small, rare CNVs – note
that for both approaches, the power drops to the nominal type I
error rate of 5% as the limit of reliable detection is approached.
This is an intuitive finding (at least in retrospect). CNV calling
pools information across markers. This is most effective for large
CNVs. Typically, however, methods for CNV calling do not make
use of CNV frequency; this is valuable information when CNVs
are common. Marker-level testing does the opposite, pooling
information across subjects before attempting to identify signifi-
cant CNVs. This is most effective when the CNV is common.
However, the marker-level approach does not take advantage of
the information provided by neighboring markers when conduct-
ing its initial tests, which is valuable information for detecting large
CNVs.
How large? How rare? In our simulations, marker-level testing
had low power to detect associations involving CNVs occurring in
5% or fewer of the subjects, while CNV-level testing had little
power to detect associations involving CNVs consisting of fewer
than 20 markers (&30 kb). However, these results provide no
more than a rough guide. Different ways of carrying out these two
approaches (such as using hidden Markov models instead of CBS)
or using different types of SNP arrays will likely affect the precise
number of markers at which one approach becomes better than
the other. The important point is that over the range of
biologically plausible values, neither CNV testing approach is
clearly superior. Indeed, the differences in power can be
considerable. For 10-marker CNVs that occur with 20%
frequency, marker-level testing was found to be over 12 times
more powerful (62% vs. 5%; case-control results), whereas for 50-
marker CNVs with 5% frequency, CNV-level testing was found to
be 4.8 times more powerful (53% vs. 11%; continuous outcome
results).
Gemcitabine study
The data were analyzed using both the pooled marker-level
testing approach and the CNV-level testing approach. To deal
with the issue of partial overlap among CNV calls, we used the
cghMCR package (available at http://www.bioconductor.org/
packages/release/bioc/html/cghMCR.html) to find minimal
common regions among the CNV calls [30]. Minimal common
regions with at least three shared gains or losses among cell lines in
the sample were considered for subsequent association testing. The
most widely shared common region consisted of 20 cell lines with a
CNV in that region.
To account for multiple comparisons with the CNV-level testing
approach, false discovery rates [31,32] were calculated. This is
somewhat conservative, as partially overlapping CNVs across cell
lines introduce dependence across the tests, thereby reducing the
effective number of independent tests. Accounting for multiple
comparisons is more straightforward with marker-level testing, as
the approach we outline in ‘‘Marker-level testing’’ directly controls
the family-wise error rate (FWER) of the overall procedure (in the
weak sense [33]).
The marker-level approach identified 8 distinct regions at a
chromosome-wide significance level of 0.05. At a false discovery
rate of 5%, the CNV-level approach identified three regions
associated with IC50. Neither of these regions overlapped with the
marker-level regions (Table 3). There were, however, regions for
which the two approaches demonstrated modest agreement
Figure 4. Power as a function of method and CNV size. The CNV-level testing approach uses a false positive CNV call rate of 0.01; the marker-
level approach uses the probit transformation. The lower dashed line represents the type I error rate, while the upper dashed line represents the
‘‘oracle’’ power that would be possible if the true CNV status were known, with no measurement error.
doi:10.1371/journal.pone.0034262.g004
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chromosome-wide significance.
We take a closer look at the region spanning 199.28–199.32 Mb
in Figure 5. This region contained 15 markers, 6 of which had
marker-level p-values below .05. At the top of the figure, the CNV-
level testing approach is depicted. In the middle of the region,
CNV calls were made for four cell lines. These lines had a mean
adjusted IC50 of 20.8, quite a bit below the mean of 0 for the
lines without a called CNV in that region (the adjustment
procedure described in ‘‘Gemcitabine pharmacogenomic study’’
centers the response to have an overall mean of 0). A Wilcoxon
rank-sum test comparing the two groups has a p-value of 0.02,
suggesting an association between the CNV and Gemcitabine
cytotoxicity that is in agreement with the one discovered by the
marker-level approach. For CNV-level testing, however, evidence
for the association is weak after adjusting for multiple comparisons.
To the left of the shaded region in Figure 5, the marker-level
approach shows no evidence of association, and indeed, no
common regions were found there (and hence, no association test
was carried out). Meanwhile, to the right of the shaded region,
Table 3. Comparison of CNV-level and marker-level tests for the Gemcitabine data.
CNV-level Marker-level Other
Position (Mb) nc p q FWER studies
Detected by CNV-level approach 12.3–12.45 3 v0:0001 0.03 w0:2
51.4–51.5 7 v0:0001 0.01 0.1–0.2 [34–36]
185.1–185.2 3 v0:0001 0.01 w0:2 [35,37–39]
11.3–11.5 3 0.7 0.9 v0:01 [35,37,40,41]
Detected by marker – level approach 41.78–41.80 v3 0.01–0.05 [36,42]
42.6–42.7 4 0.4 0.8 0.01–0.05
44.2–44.4 3 0.1 0.6 v0:01 [36]
102.5–102.7 6 0.4 0.8 v0:01
132.5–132.6 v3 v0:01 [34,43]
139.6–139.8 5 0.2 0.6 0.01–0.05
199.28–199.32 4 0.02 0.3 0.01–0.05 [1,3,34,35,37,40,44–48]
nc~number of CNV calls in that region. If ncv3, no association test was carried out, hence the blank entries. For the marker-level tests, a FWER of 0.01–0.05 means that
controlling the FWER at the a~0:05 level, we obtain a segmentation in this region, but that if we control the FWER at the a~0:01 level, we do not.
doi:10.1371/journal.pone.0034262.t003
Figure 5. Plot of {log10 (p) from Gemcitabine marker-level tests as a function of position along the chromosome. The shaded region
denotes a region of significant elevation, as detected by the methods described in ‘‘Marker-level testing’’. The top of the plot contains annotations
describing the results of the CNV-level analysis in three distinct regions. IC50CNV is the mean adjusted IC50 for cell lines with a called CNV in that
region; IC50Ref is the mean adjusted IC50 for cell lines without a called CNV in that region.
doi:10.1371/journal.pone.0034262.g005
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approach, a common region consisting of nine cell lines was found.
However, this region showed no association with the outcome: the
mean adjusted IC50 was nearly the same for those lines with a
CNV in the common region and those without (p~0:9).
Not all regions demonstrated this level of agreement. For
example, consider the region 102.52–102.73 Mb, plotted at the
bottom of Figure 3. It is obvious even to the naked eye that some
sort of association is present, and yet no common regions were
observed in this span of the chromosome. Clearly, there seems to
be information present in the continuous LRR measurements that
is lost when an attempt at CNV calling is made. One possibility is
that this region harbors a number of small variants that cannot be
detected by CNV calling due to an insufficient number of markers
per CNV, but that do not stand in the way of detection using the
single-marker approach.
There were also regions detected by the CNV-level approach
and not the marker-level approach, such as the region 12.31–
12.45 Mb. This region has a large number of markers (241),
making the individual CNVs easy to recognize and call.
Furthermore, the two cell lines with the highest IC50 levels both
had CNVs in this region, and the CNV-level association test was
highly significant (p~0:00007, q~0:01). However, the CNV was
also rare, present in only 3 out of 172 cell lines. The simulation
results demonstrate that the marker-level approach has lower
power that the CNV-level approach when the CNV is rare, which
helps to explain why no association was found in this region using
the marker-level approach.
CNV analysis of the of the gemcitabine pharmacogenomics
study involving the Human Variation Panel has also been carried
out by Kalari et al. [49]. In their analysis, they discovered 775
CNVs with allele frequencies w1% in 102 regions across the
genome, including 12 regions on chromosome 3. Using a CNV-
level testing approach, they reported five CNV regions to be
associated with gemcitabine IC50; none, however, were located on
chromosome 3.
Discussion
We have explored two different approaches to testing for
associations between copy number and phenotype. Our results
show that CNV-level testing has greater power to detect
associations involving large, rare CNVs, while marker-level testing
has greater power to detect associations involving small, common
CNVs.
Of course, there are other concerns besides power. Plots such as
those in Figures 3 and 5 may be of descriptive interest regardless of
the formal approach to association testing used. Circular binary
segmentation is rather computationally intensive, and is the
primary computational burden in the analysis. In a CNV-level
analysis, CBS must be run n times (once for each subject), whereas
in a marker-level analysis, it needs to be run only once (on the p-
values). For our analysis of the gemcitabine data in the Results
section, carried out on an Intel 3.00 GHz processor, the marker-
level analysis required 22.6 seconds, while the CNV-level analysis
required 52.5 minutes. Furthermore, issues of partially overlap-
ping CNVs and correction for multiple testing are far more
complicated and challenging in the CNV-level approach than the
marker-level approach.
We used a relatively simple method (CBS) for CNV calling in
this study. There are a variety of competing tools, and indeed, this
is an active area of methodological development. Certainly, the
specific numbers in the power calculations would differ for other
CNV calling tools. However, the main message of this article is the
general trend and fundamental differences between the CNV-level
and marker-level approaches, regardless of the specific techniques
used for CNV calling or marker-level test aggregation.
Indeed, as marker-level approaches are less well-known in the
statistical genetics community, far less work has gone into
developing methods for them, and there is undoubtedly much
room for improvement using marker-level approaches beyond the
simple approach presented here. Alternative approaches include
hidden Markov models, the fused lasso, local regression and
kernel-based approaches [50–54]. Nor is it clear that pooling p-
values is the best approach; a more powerful approach may be to
pool test statistics instead of p-values to account for the direction of
the association. Further research is needed to compare the relative
merits of these approaches.
Furthermore, our simulations involve a very simple genetic
scenario: a small segment of DNA in which a single CNV is either
present or absent. It is important to understand the properties of
CNV- and marker-level approaches in these simple cases,
although future research involving more complicated scenarios is
also needed.
Our findings are important for two reasons. First, as both of
these approaches are used in practice, it is important for
researchers to be aware of their strengths and limitations for
detecting certain kinds of CNV-phenotype associations. In
practice, the genetic mechanism is unknown, and may be due to
rare, large CNVs or small, common CNVs – or a combination of
both. An over-reliance on either approach is likely to lead to
missing certain types of associations, as we observed in our analysis
of the gemcitabine data.
Second, these findings highlight the inadequacy of current
approaches and the need to develop methods capable of
simultaneously pooling information across both markers and
subjects for CNV detection and association studies. Indeed, several
recent articles have proposed methods along those lines [55–57].
Such methods have the potential to avoid the loss of power and
information that comes from current two-stage approaches and
deliver robust power to detect the wide variety of CNV-phenotype
associations that may exist in nature.
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